Cargando…
Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks
The metabotropic glutamate receptor subtype 5 (mGluR5) is a class C G-protein-coupled receptor (GPCR) that has been implicated in various neuronal processes and, consequently, in several neuropsychiatric or neurodevelopmental disorders. Over the past few decades, mGluR5 has become a major focus for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458693/ https://www.ncbi.nlm.nih.gov/pubmed/37631042 http://dx.doi.org/10.3390/ph16081127 |
_version_ | 1785097227004280832 |
---|---|
author | Dupont, Anne-Claire Arlicot, Nicolas Vercouillie, Johnny Serrière, Sophie Maia, Serge Bonnet-Brilhault, Frédérique Santiago-Ribeiro, Maria-Joao |
author_facet | Dupont, Anne-Claire Arlicot, Nicolas Vercouillie, Johnny Serrière, Sophie Maia, Serge Bonnet-Brilhault, Frédérique Santiago-Ribeiro, Maria-Joao |
author_sort | Dupont, Anne-Claire |
collection | PubMed |
description | The metabotropic glutamate receptor subtype 5 (mGluR5) is a class C G-protein-coupled receptor (GPCR) that has been implicated in various neuronal processes and, consequently, in several neuropsychiatric or neurodevelopmental disorders. Over the past few decades, mGluR5 has become a major focus for pharmaceutical companies, as an attractive target for drug development, particularly through the therapeutic potential of its modulators. In particular, allosteric binding sites have been targeted for better specificity and efficacy. In this context, Positron Emission Tomography (PET) appears as a useful tool for making decisions along a drug candidate’s development process, saving time and money. Thus, PET provides quantitative information about a potential drug candidate and its target at the molecular level. However, in this area, particular attention has to be given to the interpretation of the PET signal and its conclusions. Indeed, the complex pharmacology of both mGluR5 and radioligands, allosterism, the influence of endogenous glutamate and the choice of pharmacokinetic model are all factors that may influence the PET signal. This review focuses on mGluR5 PET radioligands used at several stages of central nervous system drug development, highlighting advances and setbacks related to the complex pharmacology of these radiotracers. |
format | Online Article Text |
id | pubmed-10458693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104586932023-08-27 Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks Dupont, Anne-Claire Arlicot, Nicolas Vercouillie, Johnny Serrière, Sophie Maia, Serge Bonnet-Brilhault, Frédérique Santiago-Ribeiro, Maria-Joao Pharmaceuticals (Basel) Review The metabotropic glutamate receptor subtype 5 (mGluR5) is a class C G-protein-coupled receptor (GPCR) that has been implicated in various neuronal processes and, consequently, in several neuropsychiatric or neurodevelopmental disorders. Over the past few decades, mGluR5 has become a major focus for pharmaceutical companies, as an attractive target for drug development, particularly through the therapeutic potential of its modulators. In particular, allosteric binding sites have been targeted for better specificity and efficacy. In this context, Positron Emission Tomography (PET) appears as a useful tool for making decisions along a drug candidate’s development process, saving time and money. Thus, PET provides quantitative information about a potential drug candidate and its target at the molecular level. However, in this area, particular attention has to be given to the interpretation of the PET signal and its conclusions. Indeed, the complex pharmacology of both mGluR5 and radioligands, allosterism, the influence of endogenous glutamate and the choice of pharmacokinetic model are all factors that may influence the PET signal. This review focuses on mGluR5 PET radioligands used at several stages of central nervous system drug development, highlighting advances and setbacks related to the complex pharmacology of these radiotracers. MDPI 2023-08-10 /pmc/articles/PMC10458693/ /pubmed/37631042 http://dx.doi.org/10.3390/ph16081127 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dupont, Anne-Claire Arlicot, Nicolas Vercouillie, Johnny Serrière, Sophie Maia, Serge Bonnet-Brilhault, Frédérique Santiago-Ribeiro, Maria-Joao Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks |
title | Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks |
title_full | Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks |
title_fullStr | Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks |
title_full_unstemmed | Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks |
title_short | Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks |
title_sort | metabotropic glutamate receptor subtype 5 positron-emission-tomography radioligands as a tool for central nervous system drug development: between progress and setbacks |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458693/ https://www.ncbi.nlm.nih.gov/pubmed/37631042 http://dx.doi.org/10.3390/ph16081127 |
work_keys_str_mv | AT dupontanneclaire metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks AT arlicotnicolas metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks AT vercouilliejohnny metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks AT serrieresophie metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks AT maiaserge metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks AT bonnetbrilhaultfrederique metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks AT santiagoribeiromariajoao metabotropicglutamatereceptorsubtype5positronemissiontomographyradioligandsasatoolforcentralnervoussystemdrugdevelopmentbetweenprogressandsetbacks |